New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
10:45 EDTSRPTLeerink still cautious on FDA approving eteplirsen with existing data
Leerink says it continues to have reservations that the FDA will approve Sarepta's eteplirsen on its existing data set. The firm thinks today's news supports its belief that the FDA is "kicking the can down the road" on an eteplirsen decision until it obtains more analyzed data. Leerink reiterates a Market Perform rating on Sarepta with a $31 price target.
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SRPT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use